Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/23
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/07/23
Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant CancersGlobeNewsWire • 07/24/23
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid TumorsGlobeNewsWire • 07/10/23
Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/09/23
Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingGlobeNewsWire • 04/18/23
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant CancersGlobeNewsWire • 04/03/23
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/27/23
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingGlobeNewsWire • 03/15/23
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Tango Therapeutics, Inc (TNGX) InvestigationBusiness Wire • 02/21/23
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business UpdatesGlobeNewsWire • 01/25/23
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/22
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/10/22
These Were the Five Best and Worst Performing Small-cap Stocks in October 202224/7 Wall Street • 11/08/22
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 11/01/22
Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/19/22